KROCUS trial (fulzerasib): what clinicians have said so far
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
- NCT05756153 ↗
- Completed
- Genfleet Therapeutics (Shanghai) Inc.
- Standard size, estimated: 151–300 verified statements once built
We haven't built an HCP commentary report on KROCUS (fulzerasib plus cetuximab in previously untreated advanced KRAS G12C-mutated NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 21 indexed sources
Automated from all 21 indexed sources (Nov 2023 – Apr 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether a chemotherapy-free fulzerasib-cetuximab regimen can replace PD-1-based first-line therapy, alone or with chemotherapy
- Whether the combination controls brain metastases in KRAS G12C NSCLC
- Whether PD-L1 or EGFR expression predicts benefit from fulzerasib plus cetuximab
- Whether cetuximab blocks EGFR feedback and delays adaptive resistance to KRAS G12C inhibition
Indexed commentary on KROCUS so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 17 posts on X, typically up to 75 once built | |
| 2 YouTube videos, typically up to 9 once built | |
| 2 podcast episodes, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Advance Non-small Cell Lung Cancer
- Interventions
- GFH925; Cetuximab
- Arms
- GFH925+Cetuximab · Experimental
- Enrollment
- 47
- Primary outcomes
- Phase Ib: adverse events
- Phase II: objective response rate
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Start
- Apr 25, 2023
- Primary completion
- Apr 30, 2025
- Results posted
- No
- Registry record
- NCT05756153 · updated Aug 12, 2025
Publications
linked from the registry- Gregorc V, Majem M, Lo Russo G, Maio M, Salvagni S, Gutierrez-Calderon V, Gonzalez-Cao M, Sandiego Contreras S, Koumarianou A, Bearz A, Bernabe-Caro R, Viteri S, de Sanmamed MF, Zagouri F, Moran Bueno T, Lazzari C, Martinez-Recio S, Gimenez-Capitan A, Zhang Y, Shan Y, Zhu H, Zhao C, Shen H, Wang Y, Rosell R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. Lancet Oncol. 2026 Apr;27(4):432-441. doi: 10.1016/S1470-2045(25)00764-8. PubMed 41926959